Literature DB >> 23180162

Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs.

Nicky Thomas1, René Holm, Mats Garmer, Jens Jakob Karlsson, Anette Müllertz, Thomas Rades.   

Abstract

This study investigates the potential of supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS) to improve the bioavailability of poorly water-soluble drugs compared to conventional SNEDDS. Conventional SNEDDS contained simvastatin (SIM) at 75% of the equilibrium solubility (S (eq)). Super-SNEDDS containing SIM at 150 and 200% of S (eq) were produced by subjecting the SNEDDS preconcentrates to a heating and cooling cycle. The super-SNEDDS were physically stable over 10 months. During in vitro lipolysis of SNEDDS and super-SNEDDS the SIM concentration in the aqueous phase increased for the first 30 min almost proportional to the drug loads and amounts of preconcentrate employed. The 200% drug-loaded super-SNEDDS generated an amorphous SIM precipitate at the end of in vitro lipolysis. In vivo, the relative bioavailability of SIM from super-SEDDDS increased significantly to 180 ± 53.3% (p = 0.014) compared to the dosing of two capsules of (dose equivalent) 75% drug-loaded SNEDDS. A significant increase in the terminal half-life of elimination was observed for super-SNEDDS (2.3 ± 0.6 h) compared to conventional SNEDDS (1.4 ± 0.3 h) as well as a decreased area under the curve ratio of the SIM metabolite simvastatin acid to the parent compound (0.57 ± 0.20 and 0.90 ± 0.3), possibly due to a combination of saturation effects on presystemic metabolising enzymes and prolonged absorption along the small intestine. In summary, this study demonstrated that super-SNEDDS are a viable formulation option to enhance the bioavailability of poorly water-soluble drugs such as simvastatin while reducing the pill burden by an increased drug load of SNEDDS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180162      PMCID: PMC3535117          DOI: 10.1208/s12248-012-9433-7

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  29 in total

Review 1.  Solubilizing excipients in oral and injectable formulations.

Authors:  Robert G Strickley
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

Review 2.  Oral lipid-based formulations.

Authors:  David J Hauss
Journal:  Adv Drug Deliv Rev       Date:  2007-05-26       Impact factor: 15.470

3.  Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS.

Authors:  Thao Do Thi; Michiel Van Speybroeck; Valery Barillaro; Johan Martens; Pieter Annaert; Patrick Augustijns; Jan Van Humbeeck; Jan Vermant; Guy Van den Mooter
Journal:  Eur J Pharm Sci       Date:  2009-09-24       Impact factor: 4.384

4.  The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats.

Authors:  Zhiwen Zhang; Huihui Bu; Zhiwei Gao; Yan Huang; Fang Gao; Yaping Li
Journal:  Int J Pharm       Date:  2010-05-08       Impact factor: 5.875

5.  Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation.

Authors:  J M Kovarik; E A Mueller; J B van Bree; W Tetzloff; K Kutz
Journal:  J Pharm Sci       Date:  1994-03       Impact factor: 3.534

6.  Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation.

Authors:  E A Mueller; J M Kovarik; J B van Bree; W Tetzloff; J Grevel; K Kutz
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

7.  Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation.

Authors:  E A Mueller; J M Kovarik; J B van Bree; J Grevel; P W Lücker; K Kutz
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

8.  Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.

Authors:  A T Serajuddin; S A Ranadive; E M Mahoney
Journal:  J Pharm Sci       Date:  1991-09       Impact factor: 3.534

9.  Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms.

Authors:  Marija Tubic-Grozdanis; John M Hilfinger; Gordon L Amidon; Jae Seung Kim; Paul Kijek; Petra Staubach; Peter Langguth
Journal:  Pharm Res       Date:  2008-01-24       Impact factor: 4.200

10.  Clinical studies with oral lipid based formulations of poorly soluble compounds.

Authors:  Dimitrios G Fatouros; Ditte M Karpf; Flemming S Nielsen; Anette Mullertz
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

View more
  18 in total

1.  Bioavailability of cinnarizine in dogs: effect of SNEDDS loading level and correlation with cinnarizine solubilization during in vitro lipolysis.

Authors:  Anne T Larsen; Pernilla Åkesson; Anna Juréus; Lasse Saaby; Ragheb Abu-Rmaileh; Bertil Abrahamsson; Jesper Østergaard; Anette Müllertz
Journal:  Pharm Res       Date:  2013-08-15       Impact factor: 4.200

2.  Influence of drug load and physical form of cinnarizine in new SNEDDS dosing regimens: in vivo and in vitro evaluations.

Authors:  Scheyla D V S Siqueira; Anette Müllertz; Kirsten Gräeser; Georgia Kasten; Huiling Mu; Thomas Rades
Journal:  AAPS J       Date:  2017-01-09       Impact factor: 4.009

3.  The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS).

Authors:  Maria Høtoft Michaelsen; Kishor M Wasan; Olena Sivak; Anette Müllertz; Thomas Rades
Journal:  AAPS J       Date:  2016-01       Impact factor: 4.009

4.  In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate.

Authors:  Nicky Thomas; Katharina Richter; Thomas B Pedersen; René Holm; Anette Müllertz; Thomas Rades
Journal:  AAPS J       Date:  2014-04-02       Impact factor: 4.009

5.  Quantifying In Vivo Luminal Drug Solubilization -Supersaturation-Precipitation Profiles to Explain the Performance of Lipid Based Formulations.

Authors:  Yusuke Tanaka; Erin Tay; Tri-Hung Nguyen; Christopher J H Porter
Journal:  Pharm Res       Date:  2020-02-03       Impact factor: 4.200

6.  Toward the establishment of standardized in vitro tests for lipid-based formulations, part 6: effects of varying pancreatin and calcium levels.

Authors:  Philip Sassene; Karen Kleberg; Hywel D Williams; Jean-Claude Bakala-N'Goma; Frédéric Carrière; Marilyn Calderone; Vincent Jannin; Annabel Igonin; Anette Partheil; Delphine Marchaud; Eduardo Jule; Jan Vertommen; Mario Maio; Ross Blundell; Hassan Benameur; Christopher J H Porter; Colin W Pouton; Anette Müllertz
Journal:  AAPS J       Date:  2014-10-02       Impact factor: 4.009

Review 7.  Current Status of Supersaturable Self-Emulsifying Drug Delivery Systems.

Authors:  Heejun Park; Eun-Sol Ha; Min-Soo Kim
Journal:  Pharmaceutics       Date:  2020-04-16       Impact factor: 6.321

Review 8.  The Precipitation Behavior of Poorly Water-Soluble Drugs with an Emphasis on the Digestion of Lipid Based Formulations.

Authors:  Jamal Khan; Thomas Rades; Ben Boyd
Journal:  Pharm Res       Date:  2015-11-23       Impact factor: 4.200

9.  Novel cationic supersaturable nanomicellar systems of raloxifene hydrochloride with enhanced biopharmaceutical attributes.

Authors:  Atul Jain; Rajpreet Kaur; Sarwar Beg; Varun Kushwah; Sanyog Jain; Bhupinder Singh
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

10.  New Insights into Using Lipid Based Suspensions for 'Brick Dust' Molecules: Case Study of Nilotinib.

Authors:  Niklas J Koehl; René Holm; Martin Kuentz; Brendan T Griffin
Journal:  Pharm Res       Date:  2019-02-22       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.